• TempraMed signed a non-binding LOI dated July 30, 2026 with CPO Greece for exclusive distribution of VIVI Cap, VIVI Epi.
• Exclusivity would depend on a definitive distribution agreement plus minimum purchase obligations.
• CPO would need to lift combined annual purchases by at least 20% year over year to keep exclusivity.
• Transfer pricing plus first-year minimum unit commitments will be set in the definitive agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempramed Technologies Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609010645NEWSFILECNPR____20260901_312252_1) on September 01, 2026, and is solely responsible for the information contained therein.